Immunogenicity, Reactogenicity and Safety of a Combined DTPa-IPV Vaccine Compared with Separate DTPa and IPV Vaccines in Healthy Korean Infants
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose : To compare immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (DTPa-IPV, InfanrixTM IPV, GlaxoSmithKline Biologicals) with co-administration of commercially available DTPa and IPV vaccines at separate injection sites (DTPa+IPV). Methods : A total of 458 infants aged 8-12 weeks were randomized to receive three-dose primary vaccination at 2, 4 and 6 months with DTPa-IPV or DTPa+IPV. Blood samples were collected pre and post vaccination for measurement of immune responses. Reactogenicity was assessed following each dose using diary cards. Results : One month post-dose 3, seroprotection rates for anti-diphtheria, anti-tetanus and anti-poliovirus types 1, 2 and 3 were ≥99.5% and vaccine response rates to pertussis antigens were at least 98.6% in both DTPa-IPV and DTPa + IPV groups. Non-inferiority between the groups was demonstrated based on pre-defined statistical criteria. Incidences of both local and systemic symptoms were within the same range across both groups with grade 3 symptoms reported following no more than 4.3% of DTPa-IPV doses and 4.5% of DTPa + IPV doses. Two serious adverse events (both pyrexia) after DTPa-IPV administration were considered vaccine-related. Both infants recovered fully. Conclusion : Combined DTPa-IPV vaccine was immunogenic and well tolerated when used as a three-dose primary vaccination course in Korean infants. DTPa-IPV could be incorporated into the Korean vaccination schedule, reducing the number of injections required to complete primary immunization.
Abstract
Purpose : To compare immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (DTPa-IPV, InfanrixTM IPV, GlaxoSmithKline Biologicals) with co-administration of commercially available DTPa and IPV vaccines at separate injection sites (DTPa+IPV). Methods : A total of 458 infants aged 8-12 weeks were randomized to receive three-dose primary vaccination at 2, 4 and 6 months with DTPa-IPV or DTPa+IPV. Blood samples were collected pre and post vaccination for measurement of immune responses. Reactogenicity was assessed following each dose using diary cards. Results : One month post-dose 3, seroprotection rates for anti-diphtheria, anti-tetanus and anti-poliovirus types 1, 2 and 3 were ≥99.5% and vaccine response rates to pertussis antigens were at least 98.6% in both DTPa-IPV and DTPa + IPV groups. Non-inferiority between the groups was demonstrated based on pre-defined statistical criteria. Incidences of both local and systemic symptoms were within the same range across both groups with grade 3 symptoms reported following no more than 4.3% of DTPa-IPV doses and 4.5% of DTPa + IPV doses. Two serious adverse events (both pyrexia) after DTPa-IPV administration were considered vaccine-related. Both infants recovered fully. Conclusion : Combined DTPa-IPV vaccine was immunogenic and well tolerated when used as a three-dose primary vaccination course in Korean infants. DTPa-IPV could be incorporated into the Korean vaccination schedule, reducing the number of injections required to complete primary immunization.
참고문헌 (29)
- "Immunization surveillance, assessment and monitoring. Immunization Profile - Republic of Korea" (2009)[URL]
- The Korean Pediatric Society, "DTaP and Td vaccines. In: Immunization Guideline. 6th edition" (2008), The Korean Pediatric Society
- 강진한, "우리나라 영아에서 3가 정제 백일해 항원 DTaP 백신의면역원성 및 안전성", Korean Journal of Pediatrics, 50(4), pp.355~362 (2007), 대한소아과학회
- Kim HH, "Investigation on the immunity to pertussis in Korea", J Korean Soc Microbiol, 34, pp.583~589 (1999)
- Shek LP, "Comparative study of the reactogenicity of a threecomponent acellular pertussis vaccine and whole-cell pertussis vaccine administered to healthy Singaporean infants", Southeast Asian J Trop Med Public Health, 34, pp.863~868 (2003)
- Jefferson T, "Systematic review of the effects of pertussis vaccines in children", Vaccine, 21, pp.2003~2014 (2003)
- "Division of Vaccine Preventable Disease Control and National Immunization Program", Korea Centers for Disease Control and Prevention Monthly Newsletter, 5, pp.28~ (2007)
- "Korea Centers for Disease Control and Prevention"[URL]
- 유신, "소아 백일해 감염의 유행 및 임상 양상(2000. 3-2001. 3)", Korean Journal of Pediatrics, 45(5), pp.7~608 (2002), 대한소아과학회
- Sun Jun Kim, "Vaccine-associated Paralytic Poliomyelitis: A Case Report of Flaccid Monoparesis after Oral Polio Vaccine", Journal of Korean Medical Science, 22(2), pp.362~364 (2007), 대한의학회
- "Major milestone reached in global polio eradication: Western Pacific region is certified polio-free. Press release WHO/71 29 October 2000" (2000)[URL]
- Happe LE, "Combination vaccine use and vaccination quality in a managed care population", Am J Manag Care, 13, pp.506~512 (2007)
- Kalies H, "The use of combination vaccines has improved timeliness of vaccination in children", Pediatr Infect Dis J, 25, pp.507~512 (2006)
- Schmitt HJ, "Efficacy of acellular pertussis vaccine in early childhood after household exposure", JAMA, 275, pp.37~41 (1996)
- Greco D, "A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis", N Engl J Med, 334, pp.341~348 (1996)
- Camargo ME, "Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum", J Clin Microbiol, 20, pp.772~774 (1984)
- Melville-Smith ME, "A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera", J Biol Stand, 11, pp.137~144 (1983)
- Schmitt HJ, "Primary vaccination of infants with diphtheria- tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections", J Pediatr, 137, pp.304~312 (2000)
- World Health Organization (WHO), "procedure for determining immunity to poliovirus using the microneutralization test", WHO, Gen 93, pp.1993, ~
- Black S, "GlaxoSmith- Kline DTaP-IPV Vaccine Study Group. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years", Vaccine, 24, pp.6163~6171 (2006)
- Black S, "Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age", Pediatr Infect Dis J, 27, pp.341~346 (2008)
- Marshall H, "A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years", Vaccine, 24, pp.6120~6128 (2006)
- Jacquet JM, "Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: A review", Vaccine, 24, pp.2440~2448 (2006)
- Nilsson L, "A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age", Scand J Infect Dis, 37, pp.221~229 (2005)
- Lin TY, "Safety and immunogenicity of a diphtheria, tetanus and acellular-pertussis-inactivated poliovirus vaccine", Heamophilus influenza type b combination vaccine administered to Taiwanese infants at 2, 4 and 6 months of age, 2003, pp.26, 315~322
- Begue PC, "Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussisinactivated poliovirus vaccine and diphtheria-tetanusinactivated poliovirus vaccine in preadolescents", Pediatr Infect Dis J, 17, pp.804~809 (1998)
- Pace D, "A new combination Haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants", Pediatr Infect Dis J, 26, pp.1057~1059 (2007)
- Weston WM, "Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years", Expert Rev Vaccines, 7, pp.1309~1320 (2008)